Similar Search Results

Was part D a giveaway to the pharmaceutical industry?

Newhouse, Joseph P.; Seiguer, Erica; Frank, Richard G. - In: Inquiry : a journal of health care organization, … 44 (2007) 1, pp. 15-25

Persistent link: https://www.econbiz.de/10003570316

An overview of Henry Grabowski's scholarly contributions

Berndt, Ernst R. - In: International journal of the economics of business 18 (2011) 2, pp. 151-154

Persistent link: https://www.econbiz.de/10009298479

Opportunities for improving the drug development process : results from a survey of industry and the FDA

Berndt, Ernst R.; Gottschalk, Adrian H. B.; Strobeck, … - In: Innovation policy and the economy 6 (2006), pp. 91-121

Persistent link: https://www.econbiz.de/10003375038

Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984 Waxman-Hatch legislation

Berndt, Ernst R.; Aitken, Murray L. - 2010

"The NBER Bulletin on Aging and Health provides summaries of publications like this. You can sign up to receive the NBER Bulletin on Aging and Health by email. The landmark Waxman-Hatch Act of 1984 represented a "grand compromise" legislation that sought to balance incentives for innovation by...

Persistent link: https://www.econbiz.de/10008688817

Characterizing markets for biopharmaceutical innovations : do biologics differ from small molecules?

Trusheim, Mark; Aitken, Murray L.; Berndt, Ernst R. - 2010

Persistent link: https://www.econbiz.de/10003976203

The effect of FDA advisories on branded pharmaceutical firms' valuations and promotion efforts

Conti, Rena M.; Huskamp, Haiden A.; Berndt, Ernst R. - 2011

"The NBER Bulletin on Aging and Health provides summaries of publications like this. You can sign up to receive the NBER Bulletin on Aging and Health by email. The US Food and Drug Administration (FDA) expends considerable efforts in regulating medications approved for use. Yet the impact of...

Persistent link: https://www.econbiz.de/10009374023

Characterizing markets for biopharmaceutical innovations : do biologics differ from small molecules?

Trusheim, Mark R.; Aitken, Murray L.; Berndt, Ernst R. - In: Forum for health economics & policy : an evolving … 13 (2010) 1, pp. 1-43

Persistent link: https://www.econbiz.de/10009616664

The heterogeneity of concentrated prescribing behavior : theory and evidence from antipsychotics

Berndt, Ernst R.; Gibbons, Robert; Kolotilin, Anton; … - In: Journal of health economics 40 (2015), pp. 26-39

Persistent link: https://www.econbiz.de/10011439946

The US pharmaceutical industry : why major growth in times of cost containment?

Berndt, Ernst R. - In: Health affairs : at the intersection of health, health … 20 (2001) 2, pp. 100-114

Persistent link: https://www.econbiz.de/10001570941

The roles of marketing, product quality, and price competition in the growth and composition of the US antiulcer drug industry

Berndt, Ernst R.; Bui, Linda T. M.; Reiley, David H.; … - In: The economics of new goods : [contains revised versions …, (pp. 277-322). 1997

Persistent link: https://www.econbiz.de/10001322683